Uzbekistan Approves Initial Local Version of Danish Obesity Medication Ozempic

Uzbekistan has registered Semavik, a Russian-produced medication containing semaglutide, designed to treat type 2 diabetes and obesity. This marks the first local equivalent of the Danish drug Ozempic in the country. The approval addresses the increasing prevalence of metabolic diseases.

Uzbekistan Approves Initial Local Version of Danish Obesity Medication Ozempic

Tashkent, Uzbekistan – The pharmaceutical firm Geropharm, based in Russia, has successfully registered Semavik in Uzbekistan. This drug, featuring the active component semaglutide, is designed for managing both type 2 diabetes and obesity.

According to the company's press release, Semavik represents the first Russian-produced biosimilar to the Danish medication Ozempic, and it is currently accessible to patients. Health tracking apps like Shotlee can help monitor effectiveness of such medications.

Data from the World Health Organization indicates that approximately 30% of Uzbekistan's population, equating to nearly one in three residents, is affected by obesity. Furthermore, the International Diabetes Federation reported that diabetes cases in the country reached 1.5 million in 2024.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

Geropharm's representatives have pointed out that these statistics underscore the increasing strain of metabolic disorders on the healthcare infrastructure and reinforce the demand for readily available and effective treatment alternatives.

Prior to this, Geropharm had already secured registration for Semavik in Azerbaijan, Kazakhstan, and Tajikistan.

Source Information

Originally published by UzDaily.uz.Read the original article →

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Health & Wellness

What's the Deal with Peptides? The Hyped Market Under FDA Review

An in-depth look at the FDA's review of unregulated peptide therapy, the safety concerns raised by experts, and the conflict between industry demand and clinical evidence.

8 min read

Health & Wellness

Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program

Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.

8 min read

Medical Research

Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials

Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.

7 min read

Same topic: Pharmaceuticals

All Pharmaceuticals articles →

Weight Loss

Why I Lost Virtually No Weight on Wegovy and Mounjaro

Explore the real-world experience of a patient who spent thousands on GLP-1 injections without significant results, and learn what worked instead.

7 min read

Health & Wellness

GP's Verdict on GLP-1 Tablet Rollout: A Damp Squib?

A UK GP shares his observations on the limited uptake of new GLP-1 weight loss tablets, suggesting patient familiarity with injections and daily dosing challenges may be factors.

8 min read

Health & Wellness

Fat Loss with GLP-1s, Muscle Loss Concerns: What Users Need to Know

GLP-1 medications are powerful tools for weight loss, but concerns are emerging about potential muscle mass loss. This article delves into what users need to know about preserving lean body mass and maintaining cardiorespiratory fitness alongside fat reduction.

7 min read

More in Health

Health

Novo Nordisk India Introduces Ozempic, Considering Socio-Economic Factors | Briefs

Novo Nordisk has officially launched Ozempic in India, a once-weekly GLP-1 receptor agonist for adults managing uncontrolled type 2 diabetes. Intended as an add-on therapy to diet and exercise, Ozempic arrives as India grapples with a rapidly increasing diabetes burden and generalized obesity.

1 min read

Health

Ozempic Arrives in India, Weight Loss Medication Priced Under $25 Weekly

The weight loss drug Ozempic has been introduced in India by Novo Nordisk, with a weekly cost of $24.35 for 0.25mg doses. This move occurs amidst increasing global demand for weight management solutions. India represents a significant market due to its high rates of type 2 diabetes and obesity.

2 min read

Health

Ozempic, a Diabetes Medication, Slated for India Launch This Month

Novo Nordisk is set to introduce Ozempic in India, complementing their existing semaglutide product line. This launch occurs amidst strong competition from Eli Lilly's Mounjaro. The new medication may also be prescribed for other health conditions.

1 min read